Kit ELISA sandwich Interleukin 8 (Dog IL-8) (dog): Quantitative dosage of Dog IL-8 in serum, plasma or cell culture medium. The test recognizes only the natural and recombinant forms of Dog IL-8.
Accession number
P41324
Dose range
6.14-1500 pg/ml
Sensitivity of the dosage
6 pg/ml
Calibration range
6 pg/ml to 1500 pg/ml
Dose
ELISA solid-phase sandwich
Brand
Invitrogen
Kit ELISA sandwich Interleukin 8 (Dog IL-8) (dog): Quantitative dosage of Dog IL-8 in serum, plasma or cell culture medium. The test recognizes only the natural and recombinant forms of Dog IL-8.
Kit ELISA sandwich Interleukin 8 (Dog IL-8) (dog): Quantitative dosage of Dog IL-8 in serum, plasma or cell culture medium. The test recognizes only the natural and recombinant forms of Dog IL-8.
Method principle: This ELISA solid phase sandwich test (immuno-enzymatic dose) measures the amount of target bound between a pair of matched antibodies. A specific target antibody is pre-adsorbed into the wells of the supplied microplate. Samples, standards or controls are added to these wells and bind to immobilized antibodies (capture antibodies). The sandwich is formed by adding the second antibody (detection antibody), then a substrate solution reacts with the enzyme-antibodies-target complex to produce a measurable signal. The intensity of this signal is directly proportional to the concentration of the target present in the original sample.
Rigorous validation: Each batch manufactured from this ELISA kit is checked for criteria such as sensitivity, specificity, accuracy and reproducibility from one batch to another (see the package leaflet for more information on validation).
IL-8 (Interleukine-8) is an amino acid 72 pro-inflammatory CXC chemokine called CXCL8, secreted by endothelial cells and monocytes, which acts as an important chemotactic for neutrophils as well as T cells and basophiles. Il-8, isolated for the first time from the cells of the osteosarcoma, contains the ELR pattern (the sequence of amino acids end to end N-terminal Glu-Leu-Arg) and signals via the CXCR1 and CXCR2 receptors. Cancer studies have shown a role for IL-8 in angiogenesis and tumour growth. The previous nomenclature for the IL-8 includes neutrophil 1 (NAP-1), granulocyte 1 (GCP-1) chemotactic protein, neutrophil monocyte-derived activator peptide (MONAP) and protein 3-10 C.